News – Page 1019 – Endpoints News

Finally, Celgene wins. Anemia drug luspatercept — partnered with Acceleron — scores in PhIII trial

7 years ago

AbbVie retreats as Galapagos offers mixed PhII CF data, leaving a major alliance in peril — Vertex shares surge

7 years ago

Biogen goes deep into biosimilars, slapping down $700M for a major stake in Samsung Bioepis

7 years ago

As Alexion fields applications for ALXN1210, a rival aims for the crown with head-to-head PhIII; Novo hands NBE ...

7 years ago

Amazon snaps up online pharmacy startup PillPack in latest move to disrupt healthcare

7 years ago

Touting PhIII success for arthritis drug Taltz, Eli Lilly chases rival Novartis in heated immunology race

7 years ago

Sarcoma expert George Demetri grades the latest statement on Nanobiotix's late-stage drug NBTXR3

7 years ago

Little Arsanis steers its only clinical-stage therapy to the scrap heap after a PhII implosion

7 years ago

Anemia specialist Akebia merges with Keryx on the eve of a blockbuster brawl with FibroGen

7 years ago

C-Bridge hands Nuance Biotech $35M, opening doors to more China licensing deals

7 years ago

Takeda’s old guard loses a key battle against $62B Shire buyout — but a much bigger threat looms

7 years ago

It’s a record! Biotech IPO frenzy outpaces 2017 in half the time as 4 new arrivals on Nasdaq raise $556M

7 years ago

Array wrestles FDA OK for its MEK/BRAF melanoma combo, to hit the pharmacy as Mektovi and Braftovi

7 years ago

IPO bound? Crossovers join big syndicate backing Precision BioSciences’ $110M gene editing round

7 years ago

Meet Jennifer Petter: Boston startup Arrakis celebrates a big personal transition for top exec

7 years ago

Chinese I/O player Adlai Nortye wraps $50M Series B; Amgen touts PhIII data for Remicade knockoff

7 years ago

Positive pivotal data in hand, GBT is hustling to the FDA in search of a quick OK for sickle cell drug -- but that's ...

7 years ago

Summit execs sharpen the budget ax as Duchenne MD study flops — shares routed at Sarepta partner

7 years ago

With the ink on their $25M Astellas deal still drying, Aquinox shares get blasted on PhIII failure

7 years ago

Neon joins the biotech IPO fiesta on Nasdaq, bagging $100M in the latest display of enthusiasm for drug developers

7 years ago

AstraZeneca, Merck score a blockbuster advance as Lynparza comes through in frontline ovarian cancer

7 years ago

CAR macrophage tumor tech created by UPenn star scientists gets $53M

7 years ago

Pain Therapeutics endures yet another FDA slapdown on Remoxy — time to call it quits?

7 years ago

Roivant undergoes major restructuring, cutting and shifting its staff

7 years ago

First page Previous page 1016 1017 101810191020 1021 1022 Next page Last page